Tubulin Interacting Agents: Novel Taxanes and Epothilones

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2003 Feb 14

PMID 12583825

Citations 1

Authors

Neeraj R Agrawal

Ram Ganapathi

Tarek Mekhail

Affiliations

Soon will be listed here.

Abstract

The microtubule cytoskeleton plays an important part in cell mitosis, which relies on polymerization and depolymerization of the protein tubulin. Such established drugs as the vinca alkaloids and colchacine work by inhibiting microtubule assembly, as does paclitaxel. This article describes a variety of promising novel taxanes and epothilones with similar mechanisms of action that are in various states of preclinical and clinical development.

Citing Articles

Radiosensitizing effect of epothilone B on human epithelial cancer cells.

Baumgart T, Klautke G, Kriesen S, Kuznetsov S, Weiss D, Fietkau R Strahlenther Onkol. 2012; 188(2):177-84.

PMID: 22234539 DOI: 10.1007/s00066-011-0029-4.

References

Monzo M, Rosell R, Sanchez J, Lee J, OBrate A, Gonzalez-Larriba J . Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999; 17(6):1786-93. DOI: 10.1200/JCO.1999.17.6.1786. View

Gelmon K, Latreille J, Tolcher A, Genier L, Fisher B, Forand D . Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol. 2000; 18(24):4098-108. DOI: 10.1200/JCO.2000.18.24.4098. View

Ibrahim N, Desai N, Legha S, Soon-Shiong P, Theriault R, Rivera E . Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002; 8(5):1038-44. View

Nuijen B, Bouma M, Schellens J, Beijnen J . Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs. 2001; 19(2):143-53. DOI: 10.1023/a:1010682916808. View

Bode C, Gupta Jr M, Reiff E, Suprenant K, Georg G, Himes R . Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry. 2002; 41(12):3870-4. DOI: 10.1021/bi0121611. View

Dumontet C . Mechanisms of action and resistance to tubulin-binding agents. Expert Opin Investig Drugs. 2000; 9(4):779-88. DOI: 10.1517/13543784.9.4.779. View

Palmer C, LIVENGOOD D, WARREN A, Simpson P, JOHNSON I . The action of the vincaleukolastine on mitosis in vitro. Exp Cell Res. 1960; 20:198-201. DOI: 10.1016/0014-4827(60)90234-2. View

Bhalla K, Ibrado A, Tourkina E, Tang C, Mahoney M, Huang Y . Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 1993; 7(4):563-8. View

Advani R, Fisher G, Lum B, Jambalos C, Cho C, Cohen M . Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003; 9(14):5187-94. View

10.

McDaid H, Bhattacharya S, Chen X, He L, Shen H, Gutteridge C . Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines. Cancer Chemother Pharmacol. 1999; 44(2):131-7. DOI: 10.1007/s002800050957. View

11.

Broker L, Huisman C, Ferreira C, Rodriguez J, Kruyt F, Giaccone G . Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer Res. 2002; 62(14):4081-8. View

12.

Tishler R, Schiff P, Geard C, Hall E . Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992; 22(3):613-7. DOI: 10.1016/0360-3016(92)90888-o. View

13.

Eiseman J, Eddington N, Leslie J, MacAULEY C, Sentz D, Zuhowski M . Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol. 1994; 34(6):465-71. DOI: 10.1007/BF00685656. View

14.

Giannakakou P, Gussio R, Nogales E, Downing K, Zaharevitz D, Bollbuck B . A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A. 2000; 97(6):2904-9. PMC: 16028. DOI: 10.1073/pnas.040546297. View

15.

Woods C, Zhu J, McQueney P, Bollag D, Lazarides E . Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1995; 1(5):506-26. PMC: 2229961. View

16.

Di Leonardo A, Khan S, Linke S, Greco V, Seidita G, Wahl G . DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 1997; 57(6):1013-9. View

17.

Dumontet C, Sikic B . Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999; 17(3):1061-70. DOI: 10.1200/JCO.1999.17.3.1061. View

18.

Woodcock D, JEFFERSON S, Linsenmeyer M, Crowther P, Chojnowski G, Williams B . Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 1990; 50(14):4199-203. View

19.

Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, WOODCOCK D . Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst. 1993; 85(20):1685-90. DOI: 10.1093/jnci/85.20.1685. View

20.

Muhlradt P, Sasse F . Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity. Cancer Res. 1997; 57(16):3344-6. View